Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13869880 | 0.92 | FGFR1 (0.61) | FGFR1FLT1CHEK2HRH4ACHE | |
| SCHEMBL13869874 | 0.89 | FGFR1 (0.58) | FGFR1FLT1CHEK2HRH4ACHE | |
| SCHEMBL13869876 | 0.87 | FGFR1 (0.55) | FGFR1FLT1CHEK2HRH4ACHE | |
| SCHEMBL1621737 | 0.84 | HRH3 (0.51) | FGFR1FLT1DRD3HRH3HTR3A | |
| SCHEMBL1620865 | 0.82 | HRH3 (0.51) | FGFR1FLT1HRH3HTR3A | |
| SCHEMBL1623412 | 0.81 | FGFR1 (0.71) | FGFR1FLT1CHEK2HRH4ACHE | |
| Hydrochloric Acid SCHEMBL1622912 | 0.80 | FGFR1 (0.70) | FGFR1FLT1CHEK2HRH4ACHE | |
| SCHEMBL1620912 | 0.80 | FGFR1 (0.51) | FGFR1FLT1KCNH2HRH3HTR3A | |
| SCHEMBL2898132 | 0.80 | FGFR1 (0.51) | FGFR1FLT1KCNH2HRH3HTR3A | |
| SCHEMBL21018072 | 0.80 | CHEK2 (0.74) | FGFR1FLT1CHEK2HRH4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | claimed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | claimed |
| JP-2007505038-A | — | — | 2007-03-08 | — | — | JP | claimed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | FGFR1 883/4885FLT1 1395/4885CHEK2 233/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | FGFR1 846/4885FLT1 1207/4885CHEK2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.